[1]林振濤.重癥社區獲得性肺炎的診治[J].醫學信息,2019,(22):43-45.[doi:10.3969/j.issn.1006-1959.2019.22.014]
 LIN Zhen-tao.Diagnosis and Treatment of Severe Community Acquired Pneumonia[J].Medical Information,2019,(22):43-45.[doi:10.3969/j.issn.1006-1959.2019.22.014]
點擊復制

重癥社區獲得性肺炎的診治()
分享到:

醫學信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期數:
2019年22期
頁碼:
43-45
欄目:
綜述
出版日期:
2019-11-15

文章信息/Info

Title:
Diagnosis and Treatment of Severe Community Acquired Pneumonia
文章編號:
1006-1959(2019)22-0043-03
作者:
林振濤
(天津醫科大學寶坻臨床學院/天津市寶坻區人民醫院呼吸科,天津 301800)
Author(s):
LIN Zhen-tao
(Tianjin Medical University Baodi Clinical College/Department of Respiratory,Baodi District People's Hospital,Tianjin 301800,China)
關鍵詞:
重癥社區獲得性肺炎感染性疾病
Keywords:
Severe illnessCommunity acquired pneumoniaInfectious disease
分類號:
R563.1
DOI:
10.3969/j.issn.1006-1959.2019.22.014
文獻標志碼:
A
摘要:
隨著我國老齡化進程的加快,重癥社區獲得性肺炎(SCAP)診治受廣泛重視。SCAP多因感染毒力極強的革蘭陽性或陰性菌所致,病情嚴重,發展快,容易誘發多種嚴重并發癥,若不及時治療,可危及患者的生命安全。因此,如何診治SCAP是臨床迫切需要解決的問題之一。因多重耐藥菌的出現,抗感染難度不斷增加。故準確診斷SCAP,科學合理的治療,降低病死率,是臨床治療SCAP的主要目的。本文對SCAP發病機制、診斷標準以及治療方案作一綜述,以期為疾病的診治提供參考依據。
Abstract:
With the acceleration of the aging process in China, the diagnosis and treatment of severe community acquired pneumonia (SCAP) has received extensive attention. SCAP is caused by Gram-positive or negative bacteria with strong virulence. The disease is serious and develops rapidly. It is easy to induce a variety of serious complications. If not treated in time, it may endanger the patient's life safety. Therefore, how to diagnose and treat SCAP is one of the urgent problems that need to be solved in clinical practice. Due to the emergence of multi-drug resistant bacteria, the difficulty of anti-infection is increasing. Therefore, accurate diagnosis of SCAP, scientific and reasonable treatment, and reduce the mortality rate is the main purpose of clinical treatment of SCAP. This article reviews the pathogenesis, diagnostic criteria and treatment options of SCAP in order to provide a reference for the diagnosis and treatment of the disease.

參考文獻/References:

[1]中華醫學會呼吸病學分會.中國成人社區獲得性肺炎診斷和治療指南(2016版)[J].中華結核和呼吸雜志,2016,39(4):1-27. [2]何新華,李春盛,張海燕,等.胸腺肽α1對重癥社區獲得性肺炎的治療作用[J].中華全科醫師雜志,2014,8(6):373-376. [3]章小芳.早期無創正壓通氣治療重癥社區獲得性肺炎合并呼吸衰竭的臨床觀察及護理[J].臨床肺科雜志,2015,17(9):1205-1206. [4]陳海襄,朱維娜,隆紅艷.重癥肺炎患者病原體與證候關系的回顧性研巧[J].中國中醫急癥,2015,24(11):1959-1960. [5]Fabian M,Mirjam CC,Thomas B,et al.Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia a prospective cohort trial[J].Chest,2014,135(1):121-129. [6]陳旭巖,于學忠,沈洪,等.北京地區三級甲等綜合醫院急診科成人重癥社區獲得性炎診治現況和致病原調查[J].中國急救醫學,2013,33(6):511-515. [7]俞珍惜,劉秀云,江載芳.兒童重癥肺炎支原體肺炎急性期的相關因素分析[J].中華實用兒科臨床雜志,2011,26(4):246-249. [8]楊永山,苗淑賢,王春蘭,等.近期社區獲得性重癥肺炎的診治體會[J].當代醫學,2010,16(14):114-115. [9]Sangeeta M,Nicholas SH.Noninvasive ventilation[J].Am J Respir Crit Care Med,2013(163):540-577. [10]童國強,羅于琳,王熠,等.糖皮質激素在老年重癥社區獲得性肺炎治療中的臨床價值[J].中國老年學雜志,2014,36(24):6923-6924. [11]尹文.探尋急診重癥社區獲得性肺炎診療新舉措[J].中國急救醫學,2014,34(9):785-788. [12]鄧彩霞,張志輝.阿奇霉素聯合頭孢噻肟鈉治療兒童重癥社區獲得性肺炎的效果[J].廣東醫學,2015,24(12):1924-1925. [13]Nseir W,Farah R,Mograbi J,et al.Impact of serum C - reactiveprotein measurements in the first 2 days on the 30-day mortality inhospitalized patients with severe community - acquired pneumonia: Acohort study[J].Journal of Critical Care,2013,28(3):291-295. [14]林鳴,龐勝,詹述德,等.有創與無創正壓通氣治療重癥社區獲得性肺炎合并呼吸衰竭臨床療效觀察[J].河北醫學,2014,16(3):468-471. [15]方怡,冉丕鑫.重癥社區獲得性肺炎炎性診治情況分析[J].國外醫學(呼吸系統分冊),2015,25(1):23-29. [16]Hibert G,Gbikpi-Benissan G.Sequential use of noninvasive pressure support ventilation for acute exacerbations of chronic obstructive pulmonary disease[J].Intensive Care Med,2013,10(9): 55-61. [17]余潔,何渭基.不同治療方案在重癥社區獲得性肺炎患兒中的應用效果對比[J].臨床肺科雜志,2016,21(5):834-836. [18]崔晶,黃玉蓮,王晶,等.阿奇霉素聯合頭孢唑肟治療老年重癥社區獲得性肺炎合并心力衰竭的療效[J].武警醫學,2015,13(7):659-662. [19]喻文,羅紅敏.糖皮質激素對重癥社區獲得性肺炎住院患者高炎癥反應治療失敗的影響:一項隨機臨床試驗[J].中華危重病急救醫學,2015,27(10):804. [20]李佳鳳,王世彪,劉光華,等.β-內酰胺類與大環內酯類抗菌藥物聯合治療重癥社區獲得性肺炎療效回顧[J].臨床兒科雜志,2014,36(5):453-455.

相似文獻/References:

[1]趙建美,邵 巖.血必凈治療社區獲得性肺炎的研究進展[J].醫學信息,2018,(02):20.[doi:10.3969/j.issn.1006-1959.2018.02.009]
 ZHAO Jian-mei,SHAO Yan.Research Progress of Xuebijing in Treating Community Acquired Pneumonia[J].Medical Information,2018,(22):20.[doi:10.3969/j.issn.1006-1959.2018.02.009]
[2]包克珍,許云麗.新生兒社區獲得性肺炎的臨床特征分析[J].醫學信息,2018,(02):184.[doi:10.3969/j.issn.1006-1959.2018.02.072]
 BAO Ke-zhen,XU Yun-li.Clinical Characteristics of Neonatal Community Acquired Pneumonia[J].Medical Information,2018,(22):184.[doi:10.3969/j.issn.1006-1959.2018.02.072]
[3]郭劍波.限制熱卡營養早期應用于ICU內科重癥成年患者的效果研究[J].醫學信息,2018,(03):112.[doi:10.3969/j.issn.1006-1959.2018.03.037]
 GUO Jian-bo.Effect of Early Application of Restricted Calorie Nutrition on Severe Adult Patients in ICU Department of Internal Medicine[J].Medical Information,2018,(22):112.[doi:10.3969/j.issn.1006-1959.2018.03.037]
[4]趙建美,邵 巖,李京津.電腦中頻藥透對治療老年社區獲得性肺炎的療效分析[J].醫學信息,2018,(03):146.[doi:10.3969/j.issn.1006-1959.2018.03.052]
 ZHAO Jian-mei,SHAO Yan,LI Jing-jin.Analysis of the Efficacy of Computer Medium Frequency Drug Penetration in the Treatment of Elderly Community-acquired Pneumonia[J].Medical Information,2018,(22):146.[doi:10.3969/j.issn.1006-1959.2018.03.052]
[5]曹立杰,楊林瀛,于國云,等.N-末端腦鈉肽前體與社區獲得性肺炎患者嚴重程度關系研究[J].醫學信息,2018,(04):1.[doi:10.3969/j.issn.1006-1959.2018.04.001]
 CAO Li-jie,YANG Lin-ying,YU Guo-yun,et al.Study on the Relationship between N-terminal Brain Natriuretic Peptide Precursors and the Severity of Community-acquired Pneumonia[J].Medical Information,2018,(22):1.[doi:10.3969/j.issn.1006-1959.2018.04.001]
[6]郭楊楊,余加林.肺表面活性物質在重癥新生兒呼吸窘迫綜合征中的應用[J].醫學信息,2018,(09):42.[doi:10.3969/j.issn.1006-1959.2018.09.014]
 GUO Yang-yang,YU Jia-lin.Application of Pulmonary Surfactant in Severe Neonatal Respiratory Distress Syndrome[J].Medical Information,2018,(22):42.[doi:10.3969/j.issn.1006-1959.2018.09.014]
[7]覃 藝,鄧燕藝,賴昌生,等.554例兒童重癥手足口病的臨床特征分析[J].醫學信息,2018,(11):115.[doi:10.3969/j.issn.1006-1959.2018.11.036]
 QIN Yi,DENG Yan-yi,LAI Chang-sheng,et al.Analysis of Clinical Features of Severe Hand Foot and Mouth Disease in 554 Children[J].Medical Information,2018,(22):115.[doi:10.3969/j.issn.1006-1959.2018.11.036]
[8]董桂芬,胡麗紅,馬得宏,等.西雙版納中、老、緬邊境地區登革熱的護理干預[J].醫學信息,2018,(11):167.[doi:10.3969/j.issn.1006-1959.2018.11.055]
 DONG Gui-fen,HU Li-hong,MA De-hong,et al.Nursing Intervention of Dengue Fever in Central,Old and Myanmar Border Areas of Xishuangbanna[J].Medical Information,2018,(22):167.[doi:10.3969/j.issn.1006-1959.2018.11.055]
[9]武珊珊.喜炎平注射液治療社區獲得性肺炎臨床療效的Meta分析[J].醫學信息,2018,(14):64.[doi:10.3969/j.issn.1006-1959.2018.14.020]
 WU Shan-shan.Meta-analysis of Clinical Efficacy of Xiyanping Injection in the Treatment of Community-acquired Pneumonia[J].Medical Information,2018,(22):64.[doi:10.3969/j.issn.1006-1959.2018.14.020]
[10]徐安林,劉 忠.不同配比的哌拉西林-他唑巴坦治療 老年性社區獲得性肺炎的療效對比[J].醫學信息,2018,(15):129.[doi:10.3969/j.issn.1006-1959.2018.15.041]
 XU An-lin,LIU Zhong.Comparison of the Efficacy of Different Ratios of Piperacillin-tazobactam in Elderly Community Acquired Pneumoni[J].Medical Information,2018,(22):129.[doi:10.3969/j.issn.1006-1959.2018.15.041]

更新日期/Last Update: 2019-11-15
中国足彩网竞彩